575.42
price up icon0.73%   4.19
after-market Dopo l'orario di chiusura: 575.42
loading
Precedente Chiudi:
$571.23
Aprire:
$569.13
Volume 24 ore:
110.62K
Relative Volume:
0.29
Capitalizzazione di mercato:
$35.22B
Reddito:
$2.58B
Utile/perdita netta:
$1.06B
Rapporto P/E:
35.24
EPS:
16.33
Flusso di cassa netto:
$-1.28B
1 W Prestazione:
-0.43%
1M Prestazione:
+6.41%
6M Prestazione:
-11.77%
1 anno Prestazione:
+21.69%
Intervallo 1D:
Value
$568.67
$576.84
Intervallo di 1 settimana:
Value
$560.91
$576.84
Portata 52W:
Value
$463.92
$678.21

Argen X Se Adr Stock (ARGX) Company Profile

Name
Nome
Argen X Se Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,639
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ARGX's Discussions on Twitter

Confronta ARGX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 29.19B 3.81B -644.79M -669.77M -6.24

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-08 Aggiornamento Deutsche Bank Hold → Buy
2025-07-03 Ripresa Morgan Stanley Overweight
2025-05-13 Aggiornamento Robert W. Baird Neutral → Outperform
2025-03-17 Aggiornamento Bernstein Mkt Perform → Outperform
2025-03-12 Aggiornamento Deutsche Bank Sell → Hold
2025-01-17 Downgrade Deutsche Bank Hold → Sell
2024-11-12 Aggiornamento Wolfe Research Peer Perform → Outperform
2024-11-05 Aggiornamento Scotiabank Sector Perform → Sector Outperform
2024-11-01 Downgrade Robert W. Baird Outperform → Neutral
2024-11-01 Aggiornamento William Blair Mkt Perform → Outperform
2024-10-10 Ripresa Raymond James Strong Buy
2024-10-04 Downgrade Deutsche Bank Buy → Hold
2024-08-06 Aggiornamento Barclays Equal Weight → Overweight
2024-07-25 Aggiornamento Deutsche Bank Hold → Buy
2024-07-23 Aggiornamento Oppenheimer Perform → Outperform
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-20 Downgrade Deutsche Bank Buy → Hold
2023-12-20 Downgrade William Blair Outperform → Mkt Perform
2023-07-31 Iniziato Scotiabank Sector Perform
2023-07-24 Downgrade UBS Buy → Neutral
2023-07-17 Ripresa Evercore ISI Outperform
2023-06-15 Iniziato Societe Generale Sell
2023-05-31 Iniziato UBS Buy
2023-04-25 Iniziato Citigroup Buy
2023-03-14 Aggiornamento Robert W. Baird Neutral → Outperform
2022-12-07 Iniziato William Blair Outperform
2022-10-12 Iniziato Oppenheimer Perform
2022-07-29 Downgrade Robert W. Baird Outperform → Neutral
2022-06-28 Ripresa Stifel Buy
2022-05-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-12-08 Iniziato Wells Fargo Overweight
2021-11-29 Aggiornamento Piper Sandler Neutral → Overweight
2021-10-29 Aggiornamento Guggenheim Neutral → Buy
2021-10-28 Aggiornamento Raymond James Outperform → Strong Buy
2021-10-07 Iniziato Jefferies Buy
2021-09-23 Aggiornamento Redburn Neutral → Buy
2021-09-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-07-23 Iniziato Deutsche Bank Hold
2021-07-19 Ripresa Wolfe Research Outperform
2021-06-18 Iniziato UBS Buy
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-10 Aggiornamento H.C. Wainwright Neutral → Buy
2021-04-23 Iniziato Redburn Neutral
2021-03-05 Reiterato H.C. Wainwright Neutral
2021-02-02 Downgrade Piper Sandler Overweight → Neutral
2021-01-04 Downgrade Guggenheim Buy → Neutral
2020-08-25 Iniziato Raymond James Outperform
2020-08-19 Downgrade Evercore ISI Outperform → In-line
2020-07-29 Iniziato H.C. Wainwright Neutral
2020-02-10 Iniziato BofA/Merrill Buy
2019-11-05 Iniziato Credit Suisse Neutral
2019-10-31 Aggiornamento William Blair Mkt Perform → Outperform
2019-10-22 Iniziato JP Morgan Overweight
2019-09-27 Iniziato Wells Fargo Market Perform
2019-09-16 Ripresa Cowen Outperform
2019-06-28 Iniziato Robert W. Baird Outperform
2019-01-18 Ripresa SunTrust Buy
2019-01-04 Iniziato Morgan Stanley Overweight
2018-12-17 Iniziato Goldman Buy
2018-12-14 Iniziato Wolfe Research Outperform
2018-06-29 Iniziato Nomura Buy
2018-04-09 Iniziato SunTrust Buy
2018-01-29 Reiterato JMP Securities Mkt Outperform
Mostra tutto

Argen X Se Adr Borsa (ARGX) Ultime notizie

pulisher
Jul 21, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jul 21, 2025
pulisher
Jul 16, 2025

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jun 30, 2025

Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com

Jun 30, 2025
pulisher
May 22, 2025

argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com

May 22, 2025
pulisher
May 20, 2025

argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily

May 20, 2025
pulisher
May 14, 2025

10 Stocks Analysts Are Upgrading Today - Insider Monkey

May 14, 2025
pulisher
May 09, 2025

Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar

May 09, 2025
pulisher
May 09, 2025

Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX

May 09, 2025
pulisher
May 09, 2025

Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX

May 09, 2025
pulisher
May 08, 2025

Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily

May 08, 2025
pulisher
May 08, 2025

argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga

May 08, 2025
pulisher
Apr 30, 2025

Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily

Apr 30, 2025
pulisher
Apr 14, 2025

argenx ADR Earns Relative Strength Rating Upgrade - inkl

Apr 14, 2025
pulisher
Apr 12, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa

Apr 12, 2025
pulisher
Apr 11, 2025

Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Stifel maintains $780 target on argenx stock after FDA nod - Investing.com

Apr 11, 2025
pulisher
Apr 04, 2025

Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily

Apr 04, 2025
pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com

Mar 17, 2025
pulisher
Mar 13, 2025

TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 10, 2025

Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

argenx SE ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com

Mar 07, 2025
pulisher
Mar 04, 2025

Why This Biotech Tumbled For A Second Straight Day - Investor's Business Daily

Mar 04, 2025
pulisher
Feb 28, 2025

Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar

Feb 28, 2025
pulisher
Feb 28, 2025

Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts argenx stock price target to $720 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 27, 2025

Argenx stock target lifted to $761 by TD Cowen, maintains buy - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Argenx’s VYVGART Franchise Drives Strong Performance and Growth Prospects - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

argenx ADR earnings beat by $10.57, revenue topped estimates - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

Argenx Q4 Swings to Earnings, Operating Income Increases -February 27, 2025 at 04:00 am EST - Marketscreener.com

Feb 27, 2025

Argen X Se Adr Azioni (ARGX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
biotechnology ONC
$294.83
price down icon 0.21%
$325.64
price up icon 0.12%
$114.60
price up icon 2.84%
$28.01
price up icon 5.54%
$103.44
price up icon 0.51%
Capitalizzazione:     |  Volume (24 ore):